In stock
Semaglutide
10mg · Single vial · Lyophilized powder
Metabolic research
Semaglutide is a long-acting GLP-1 receptor agonist lyophilized compound, commonly used in metabolic and glucose regulation research.
- Studied in women's metabolic research contexts including PCOS insulin resistance models and postmenopausal glucose regulation
- Appears in GLP-1 receptor pharmacology literature investigating sex-specific pharmacokinetics
- Referenced in body composition and appetite signaling research
Order
- Dose
- 10mg
- Pack size
- Single vial
- Form
- Lyophilized powder
- Storage
- 2–8°C
In vitro laboratory research use only · Not for human or veterinary use · Batch documented · Third-party tested · Ships from Canada
§ Research
Research · Semaglutide
Overview
Semaglutide is a synthetic analog of endogenous GLP-1 with 94% structural homology to the native sequence. It incorporates a C-18 fatty diacid side chain enabling non-covalent albumin binding, extending systemic half-life to approximately 7 days. Widely used as a reference compound in GLP-1 receptor pharmacology research.
Mechanism of action
Activates the GLP-1 receptor, a G-protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, and the gastrointestinal tract. Receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, and delays gastric emptying. The C-18 modification reduces renal clearance and confers resistance to proteolytic degradation.
Key research findings
- 01
Established as a reference agonist in GLP-1 receptor binding and signaling studies across cellular and animal models.
- 02
Preclinical rodent studies characterize dose-dependent effects on glucose tolerance and insulin secretion at pharmacologically relevant exposures.
- 03
Longitudinal cardiovascular outcomes trial data (SELECT, 2023) have characterized the compound's effects on major adverse cardiovascular events in participants with established cardiovascular disease.
- 04
Clinical pharmacokinetic studies document approximately 165-hour half-life, supporting once-weekly administration regimens in investigational use.
Published references
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
The Discovery and Development of Liraglutide and Semaglutide
The information above is derived from published preclinical and clinical research. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.